免疫战略咨询专家组关于CYD-TDV登革热疫苗使用的审议
免疫战略咨询专家组(SAGE)于2016年发布首个获批登革热疫苗CYD-TDV的使用建议,2017年基于血清状态的回顾性分析显示血清阴性接种者存在重症登革热超额风险。SAGE工作组审议新数据后主要考虑两种策略:在登革热血清阳性率高于80%的人群中接种,或接种前筛查仅给血清阳性者接种。本文报告了支持2018年4月推荐接种前筛查策略的审议过程。
要点
- CYD-TDV在血清阴性接种者中观察到重症登革热超额风险。
- SAGE于2018年4月推荐接种前筛查策略。
- 仍需开发高敏特异快速血清状态检测及评估简化程序和加强剂。
核心结论
- SAGE推荐对CYD-TDV采用接种前筛查策略,仅给血清阳性个体接种。
主要发现
- 在高血清阳性率设置下疫苗提供总体人群获益,但血清阴性接种者存在重症登革热超额风险。
关键数值与推荐
- SAGE主要考虑两种策略:在登革热血清阳性率高于80%的人群中接种,或接种前筛查仅给血清阳性者接种。
临床怎么用
- 实施接种前筛查策略,仅对登革热血清阳性个体接种CYD-TDV。
局限性
- 仍需开发高敏特异快速诊断检测血清状态、简化免疫程序和评估加强剂需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Strategic Advisory Group of Experts (SAGE) on Immunization advises WHO on global policies for vaccines. In April, 2016, SAGE issued recommendations on the use of the first licenced dengue vaccine, CYD-TDV. In November, 2017, a retrospective analysis of clinical trial data, stratifying participants according to their dengue serostatus before the first vaccine dose, showed that although in high seroprevalence settings the vaccine provides overall population benefit, there was an excess risk of severe dengue in seronegative vaccinees. SAGE's working group on dengue vaccines met to discuss the new data and mainly considered two vaccination strategies: vaccination of populations with dengue seroprevalence rates above 80% or screening of individuals before vaccination, and vaccinating only seropositive individuals. We report on the deliberations that informed the recommendation of the pre-vaccination screening strategy, in April, 2018. Important research and implementation questions remain for CYD-TDV, including the development of a highly sensitive and specific rapid diagnostic test to determine serostatus, simplified immunisation schedules, and assessment of the need for booster doses.
引用
- Wilder-Smith A, Hombach J, Ferguson N, et al. Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2018. PMID: 30195995. doi:10.1016/S1473-3099(18)30494-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。